Evaluation of 3 rapid diagnostic tests (CareStart® Malaria 3 line pLDH (Pan, Pf), OptiMAL-IT® pLDH (Pan, Pf) and CareStart® 2 line pLDH (Pan) for the diagnosis of malaria in Myanmar

Author Block:
Elisabeth A. Ashley1, Malek Touabi1, Margareta Ahner2, Robert Hutagalung1, Khayae Htun2, Myo Min Lwin2, Alena Koscalova2, Eric Comte2, Prudence Hamade3, Anne-Laure Page1, Jennifer Luchavez4, Stephane Proux5, Francois Nosten5, Philippe J. Guerin1

1Epicentre, Paris, France, 2Médecins sans Frontières-Switzerland, Geneva, Switzerland, 3Médecins sans Frontières Malaria Working Group, London, United Kingdom, 4Research Institute for Tropical Medicine, Alabang, Muntinlupa City, Philippines, 5Shoklo Malaria Research Unit, Maesod, Thailand

Disclosure Block: P.J. Guerin, None.

Background
Obtaining biological confirmation of the diagnosis is considered an essential element of the detection and treatment of malaria in MSF programmes. Several Rapid Diagnosis Tests (RDTs) using monoclonal antibodies against histidine-rich protein 2 (HRP-2) produced by P. falciparum (Pf), have shown reliable results when evaluated. A second type of RDT, targeting parasite lactate dehydrogenase (pLDH), produced by all Plasmodia species, is appearing on the market increasingly, but few studies support the use of these new tests.

Methods
In an MSF-Switzerland programme in Dawei, Myanmar, 3 pLDH based RDTs were evaluated in patients presenting with clinically suspected malaria. A subset of patients with microscopically confirmed malaria had their RDTs repeated on days 2, 7 and then weekly until negative. Each RDT was read twice. At the end of the study samples of study RDTs were sent for temperature stability and quality control testing.

Results
Between Aug and Nov 2007, 1004 patients were enrolled in the study. Slide microscopy diagnosed 214 P. vivax (Pv), 99 Pf and no malaria in 650 cases. The sensitivities (Se) and specificities (Sp) of the RDTs for the detection of malaria were:

- **OptiMAL-IT®**: Pf: Se 95.2% [CI95 87.5-98.2], Sp 94.7% [92.8-96.2]; non-Pf: Se 89.6% [83.6-93.6], Sp 96.5% [94.8-97.7]; Pf alone: Se 91.4% [85.3-95.2].
- **CareStart Malaria® 3 line**: Pf: Se 93.5% [CI95 85.4-98.3], Sp 97.4% [95.9-98.3]; non-Pf: Se 78.5% [71.1-84.4], Sp 97.8% [96.3-98.7]; Pv alone: Se 80.8% [72.9-86.5].
- **CareStart Malaria® 2 line**: Pf: Se 89.1% [CI95 84.2-92.6], Sp 94.7% [92.5-96.3]; Pf alone: Se 95.6% [87.7-98.5].

Inter-observer agreement was excellent for all tests (kappa > 0.9). The median time for the RDTs to become negative was 2 days for the CareStart® tests and 7 days for OptiMAL-IT®. Only **CareStart Malaria® 2 line** passed all heat stability evaluation.

Conclusion
In this study OptiMAL-IT® RDT and the CareStart® 2 line pLDH (Pan) test met the 95% threshold of Se for detection of falciparum malaria set by WHO. The Se of both tests to detect vivax malaria exceeded 90%. However any decision to implement one of these tests should take into account the heat stability results, positive predictive value in the context in which it would be deployed and cost-effectiveness.